Diethylstilbestrol (DES), a synthetic nonsteroidal estrogen, remains a chemically significant compound despite its controversial history in human medicine. Originally prescribed to prevent miscarriages, DES was banned for use in pregnancy after being linked to severe health risks, including vaginal cancer and infertility in offspring exposed in utero . Today, its applications have pivoted to specialized veterinary medicine, research, and niche pharmaceutical uses, sustaining a global market valued at approximately $1.5 billion as of 2022 and projected to grow at a CAGR of 3.5% through 2030 . This article provides a meticulously researched overview of the ​global Diethylstilbestrol buyers list, highlighting key regions, procurement trends, and verified partners to help businesses…